Professor Alon Harris is an internationally recognized expert and leader in the field of ocular blood flow and glaucoma. Dr. Harris’ academic specialties include novel approaches to glaucoma risk management, developing monitoring techniques for ocular hemodynamics and metabolism, mathematical modeling and artificial intelligence analysis of clinical and physiological biomarkers, investigating glaucoma theraputics, generic medications, and population-based studies. Professor Harris has
Archives: Our Staffs
Our Staff Description
Barbara Calaba
Barbara was born in Michigan and grew up in various towns on the East Coast and in London, where she graduated from high school. She holds an MBA from Columbia University and a BA from Boston College. Barbara worked for ten years as a strategic brand planner in the advertising industry, working in the Paris, Milan and New York offices
Carole Darden-Lloyd
Carole Darden-Lloyd and her husband, Edward Lloyd have been married for 46 years and share one son and three grandchildren. Carole was born in Newark, NJ and grew up in neighboring Montclair. She received a BA from Sarah Lawrence College, followed by a MSW from Fordham University. She first worked in the field of foster care and then moved on
Adriana Di Polo, PhD
Dr. Di Polo is Full Professor in the Departments of Neuroscience and Ophthalmology at the University of Montreal and currently holds a Canada Research Chair in glaucoma and age-related neurodegeneration. She completed her Bachelor of Science in biology from the Universidad Central de Venezuela (Caracas, Venezuela) and her Doctorate in physiology from the University of California (Los Angeles, USA). Dr.
Eve J. Higginbotham, SM, MD
Dr. Eve Higginbotham is the inaugural Vice Dean for Inclusion and Diversity of the Perelman School of Medicine at the University of Pennsylvania, a position she assumed on August 1, 2013. She is also a Senior Fellow at the Leonard Davis Institute for Health Economics and Professor of Ophthalmology at the University of Pennsylvania. She has been a member of
Joe Rosen
Joe Rosen graduated from Syracuse University with a BS in Business Administration. His career started as a CPA with a large regional accounting firm where he quickly rose to a position in management. When an opportunity arose, he left the accounting profession to pursue a business venture in the medical field. Joe and his partners started Sera-Tec Biologicals, a business
C. Gustavo De Moraes, MD, PhD, MPH
Dr. C. Gustavo De Moraes is an Associate Professor of Ophthalmology and Medical Director of Clinical Trials of the Department of Ophthalmology at Columbia University Medical Center / New York Presbyterian Hospital. He sees patients with or at risk of developing glaucoma. His primary research interests are in novel techniques for glaucoma diagnosis, detection of progression, and treatment modalities. Based
Patricia Hill
Patricia Hill has been a psychotherapist in private practice for more than 30 years. She began her career as Assistant Director at the Health Insurance Association of America working with their lobby division and handling health agencies that were being established at that time. She soon became Director of the HIAA program. Her community service includes serving on the board
Reza Dibadj, MBA, JD
Reza Dibadj, MBA, JD is Managing Partner at Park & Dibadj, LLP, a boutique legal and business consultancy based in Silicon Valley. He works with clients to address complex questions of business law and business strategy, with a focus on addressing difficult questions in challenging environments. He is also a Professor of Law at the University of San Francisco, and
Naj Sharif, BSc (Jnt Hons), PhD, DSc, FARVO, FBPhS
Najam (Naj) Sharif, PhD, DSc (Southampton University, UK) has >34-years’ pharmaceutical drug discovery research/development experience covering neuroscience and ophthalmology. His 22-year tenure at Alcon-Novartis resulted in his contributions to the discovery, characterization, development and US FDA approvals of Patanol®/Pataday®/Pazeo® and Emadine® to treat allergic conjunctivitis, and Travatan® and Simbrinza® for the treatment of ocular hypertension / Glaucoma. Currently, he is